Related references
Note: Only part of the references are listed.Absence of Association between Use of Ertapenem and Change in Antipseudomonal Carbapenem Susceptibility Rates in 25 Hospitals
Kathryn J. Eagye et al.
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY (2010)
Introduction of Ertapenem into a Hospital Formulary: Effect on Antimicrobial Usage and Improved In Vitro Susceptibility of Pseudomonas aeruginosa
Ellie J. C. Goldstein et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
The Impact of Ertapenem Use on the Susceptibility of Pseudomonas aeruginosa to Imipenem: A Hospital Case Study
Ana Lucia L. Lima et al.
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY (2009)
International Nosocomial Infection Control Consortium report, data summary for 2002-2007, issued January 2008
Victor D. Rosenthal et al.
AMERICAN JOURNAL OF INFECTION CONTROL (2008)
Ertapenem: No effect on aerobic gram-negative susceptibilities to imipenem
Debra A. Goff et al.
JOURNAL OF INFECTION (2008)
Selectivity of ertapenem for Pseudomonas aeruginosa mutants cross-resistant to other carbapenems
DM Livermore et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2005)
Doripenem versus Pseudomonas aeruginosa in vitro:: Activity against characterized isolates, mutants, and transconjugants and resistance selection potential
S Mushtaq et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004
D Cardo et al.
AMERICAN JOURNAL OF INFECTION CONTROL (2004)
Global epidemiology of antimicrobial resistance among community-acquired and nosocomial pathogens: A five-year summary from the SENTRY Antimicrobial Surveillance Program (1997-2001)
RN Jones
SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE (2003)
In vitro activities of ertapenem (MK-0826) against recent clinical bacteria collected in Europe and Australia
DM Livermore et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2001)
Share Paper
